首页> 美国卫生研究院文献>Microbial Cell Factories >Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice
【2h】

Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice

机译:口服共同给予小鼠乳球菌表达核蛋白和霍乱毒素B亚基佐剂的抗广泛扩散的流感病毒的免疫保护

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundCurrent influenza vaccines need to be annually reformulated to well match the predicated circulating strains. Thus, it is critical for developing a novel universal influenza vaccine that would be able to confer cross-protection against constantly emerging divergent influenza virus strains. Influenza virus A is a genus of the Orthomyxoviridae family of viruses. Influenza virus nucleoprotein (NP) is a structural protein which encapsidates the negative strand viral RNA, and anti-NP antibodies play role in cross-protective immunity. Lactococcus lactis (L. lactis) is an ideal vaccine delivery vehicle via oral administration route. However, L. lactis vectored vaccine exhibits poor immunogenicity without the use of mucosal adjuvant. To enhance the immunogenicity of L. lactis vectored vaccine, cholera toxin B (CTB) subunit, one of mucosal adjuvants, is a safe adjuvant for oral route, when combined with L. lactis vectored vaccine. In this study, we hypothesized that pNZ8008, a L. lactis expression plasmid, encoding NP antigen, would be able to elicit cross-protection with the use of CTB via oral administration route.
机译:背景技术当前的流感疫苗需要每年重新配制以很好地匹配预期的循环株。因此,对于开发新型的通用流感疫苗至关重要,该疫苗能够针对不断出现的发散性流感病毒株提供交叉保护。甲型流感病毒是正粘病毒科病毒的一个属。流感病毒核蛋白(NP)是封装负链病毒RNA的结构蛋白,抗NP抗体在交叉保护性免疫中发挥作用。乳酸乳球菌(乳酸乳球菌)是通过口服途径的理想疫苗递送载体。但是,乳酸乳球菌载体疫苗在不使用粘膜佐剂的情况下表现出较差的免疫原性。为了增强乳酸乳球菌载体疫苗的免疫原性,霍乱毒素B(CTB)亚基是一种粘膜佐剂,当与乳酸乳球菌载体疫苗组合使用时,是口服途径的安全佐剂。在这项研究中,我们假设pNZ8008(一种编码NP抗原的乳酸乳球菌表达质粒)能够通过口服途径使用CTB引起交叉保护。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号